O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*
Title:
O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*
Author:
Shimizu, Toshio Lisberg, Aaron E. Sands, Jacob M. Greenberg, Jonathan Phillips, Penny Tajima, Naoyuki Kawasaki, Yui Gu, Jessie Kobayashi, Fumiaki Yamamoto, Noboru Johnson, Melissa Meric-Bernstam, Funda Yoh, Kiyotaka Garon, Edward B. Heist, Rebecca S. Spira, Alexander